Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery (AddEase)

23. juli 2026 oppdatert av: Montreal Heart Institute

Effectiveness of Adductor Canal Block in Postoperative Co-analgesia for Cardiac Surgery With Saphenous Vein Harvesting

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Montreal Heart Institute
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Planned CABG with unilateral or bilateral great saphenous vein (GSV) harvesting, without concomitant valve surgery
  • Age ≥ 18 years
  • Ability to understand the protocol and provide written informed consent
  • ASA physical status I-IV

Exclusion Criteria:

  • Refusal to participate in the study or inability to provide written informed consent
  • Contraindication to adductor canal block (e.g., local infection, allergy to local anesthetics)
  • Pre-existing chronic pain associated with chronic use of analgesic medications other than acetaminophen
  • Pre-existing peripheral neuropathy affecting the leg
  • Participation in two other interventional studies at the Montreal Heart Institute
  • Endoscopic vein harvesting performed by the surgical team instead of open saphenectomy technique

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Adductor canal bloc with bupivacaine + dexmedetomidine
Adductor canal bloc with 0,25% bupivacaine + 20 ucg of dexmedetomidine
Andre navn:
  • Pain relief arm
Placebo komparator: Control arm
Saline solution
Needle insertion mimicking the ACB procedure with injection of a saline solution

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Leg Pain at Rest
Tidsramme: Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The primary outcome will be leg pain at rest, measured using a numeric rating scale (NRS 0-10) at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total opioid consumption
Tidsramme: The first 48 postoperative hours after procedure
Cumulative amount administered, expressed in morphine milligram equivalents (MME), during the first 48 postoperative hours (conversion factors used: hydromorphone 1 mg = morphine 5 mg; fentanyl 100 µg = morphine 10 mg).
The first 48 postoperative hours after procedure
Postoperative pain unrelated to the saphenous territory
Tidsramme: Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Incidence and characterization of postoperative pain unrelated to the saphenous territory (e.g., thoracic or musculoskeletal pain), assessed at the same time points as saphenous pain using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.
Persistent Postoperative Pain
Tidsramme: At 3 and 6 months postoperatively, assessed using the NRS.

Proportion of patients reporting pain ≥4/10 at the harvest site at 3 and 6 months postoperatively, assessed using the NRS.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively, assessed using the NRS.
Overall persistent postoperative pain
Tidsramme: At 3 and 6 months postoperatively.

Proportion of patients reporting pain ≥4/10 (all sites combined) at 3 and 6 months postoperatively.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively.
Presence of hypoesthesia
Tidsramme: Numeric rating scale at 3 and 6 months.

Presence of hypoesthesia (non-painful) at the saphenectomy site at 3 and 6 months using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale at 3 and 6 months.
Neuropathic characterization
Tidsramme: At 48 hours, 3 months, and 6 months.

Quantification of the modified DN4 score at the harvest site at 48 hours, 3 months, and 6 months.

Modified DN4 ≥ 3/8: high probability of neuropathic pain Modified DN4 < 3/8: neuropathic pain unlikely

At 48 hours, 3 months, and 6 months.
Block safety
Tidsramme: Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Number of adverse events related to the adductor canal block observed during the hospital stay, including hematoma, infection, nerve injury, cardiovascular complications, motor block, and signs of local anesthetic systemic toxicity.
Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Opioid-related side effects
Tidsramme: Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Incidence of common opioid-related side effects in each group, including nausea, vomiting, and constipation.
Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Time to extubation
Tidsramme: At extubation
Time to extubation after adductor canal block
At extubation

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Use of co-analgesia
Tidsramme: Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Number of treatments used and frequency of use (lidocaine-ketamine cream, NSAIDs, gabapentinoids, etc.)
Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Postoperative quality of life
Tidsramme: At 3 and 6 months postoperatively

EQ-5D score quantification measured at 3 and 6 months postoperatively. The EQ-5D (EuroQol - 5 Dimensions) is a standardized and validated instrument used to assess health-related quality of life across two components. It is widely used in clinical research to measure the overall impact of a medical intervention on patients' functional status and well-being.

It explores five dimensions of health:

  • Mobility
  • Self-care
  • Usual activities
  • Pain / discomfort
  • Anxiety / depression

Each dimension is assessed across 5 levels of severity:

  • No problems
  • Slight problems
  • Moderate problems
  • Severe problems
  • Extreme problems / inability

The combination of responses generates a 5-digit health profile, which can be converted into an EQ-5D index.

1.0: Represents perfect health. 0.0: Represents a state considered equivalent to death. Negative values: Health states deemed "worse than death."

At 3 and 6 months postoperatively
Opioid use
Tidsramme: At 3 and 6 months postoperatively
Opioid use at 3 and 6 months postoperatively, assessed by the presence or absence of opioid use and the type of opioid used.
At 3 and 6 months postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

2. juni 2026

Først innsendt som oppfylte QC-kriteriene

23. juli 2026

Først lagt ut (Faktiske)

29. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared, as study documents are available only in French. However, upon reasonable request, the investigators will provide the study protocol, informed consent form, statistical analysis plan, and any other relevant documents.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere